Recruiting

Cancer Survivors

Sponsor:

Case Comprehensive Cancer Center

Code:

NCT07114614

Conditions

Marker; Structural

Eligibility Criteria

Sex: All

Age: 5 - 50

Healthy Volunteers: Not accepted

Interventions

Specimen #1

Specimen #2

Study Details

Brief summary:

The purpose of this research study is to investigate whether cancer survivors have higher levels of proteins called Fatty Acid Binding Proteins as well as 12 different markers of cellular senescence than people who have never had cancer. Investigators believe that these levels may be elevated in cancer survivors as a result of their cancer and the treatments they received and may put them at higher risk for chronic conditions such as high cholesterol, diabetes, high blood pressure, and obesity. This study will also compare the levels of these proteins and inflammatory markers in the blood with different aspects of cancer treatment the survivors received. Investigators are investigating if there is a correlation between levels of these proteins and markers, the type of treatment cancer survivors received, and development of metabolic conditions.

Conditions

Marker; Structural

Study ID

NCT07114614

Start date

Sep, 2026

Status verified date

Aug, 2026

Completion date

Dec, 2026

Anticipated

Primary completion date

Dec, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 5 - 50

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Diagnosis of at least one malignancy for which chemotherapy, radiation, and/or stem cell transplantation was utilized as part of treatment
  • Completed all therapeutic interventions for their malignancy and are at least 2 years off therapy
  • At least 1-year post-stem cell transplant for malignant condition

Exclusion Criteria:

1. Pregnancy at the time of the study
2. Any autoimmune condition including but not limited to lupus, rheumatoid arthritis, Crohn's disease, ulcerative colitis, type 1 diabetes, EXCEPT well-controlled autoimmune hypothyroidism for at least 6 months
3. Presence of active graft versus host disease
4. Malignancy treated using surgery only
5. Acute relapsed disease or second malignancy
6. Transplant for non-malignant conditions (e.g. cell disease, Hurler syndrome)
7. Currently taking systemic steroids and/or immunosuppressant medications
8. Acute illness necessitating hospitalization in the 30 days prior to blood draw
9. Presence of a chronic inflammatory disease EXCEPT obesity
10. Fever, active infection or inflammation, or taking antibiotics at the time of blood draw
11. A diagnosis of Type 2 diabetes or Hypertension treated with medication
12. Currently lipid lowering medications
13. Growth hormone deficiency or hypothalamic dysfunction

Study Design

Enrollment

120 participants

Anticipated

Interventions and Outcome Measures

Arms

Cancer participants

Control Group

Interventions

Specimen #1

Specimen 1 will be collected in a 10 ml SST (serum separator tube).

Specimen #2

Specimen #2 will be collected in a 10 ml SST (serum separator tube)

Primary outcome measure

  • Correlation between FABP levels and the development of risk factors for metabolic syndrome and inflammation [ Time Frame: Baseline ]
  • To determine the correlation with types of cancer-directed therapy received. [ Time Frame: Baseline ]

Central Contacts and Locations

Central contacts

Locations

Case Comprehensive Cancer Center, UH Rainbow Babies & Children's Hospital

Recruiting

Cleveland, Ohio, United States, 44106

More Information

Sponsor

Case Comprehensive Cancer Center

Last update posted

Aug 26, 2026

Last verified

Aug, 2026

Keywords

  • Fatty Acid Binding Proteins
  • Cancer Survivors
  • FABP4 and FABP5

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Case Comprehensive Cancer Center on 2026-08-26.